English Page

Our Science-based Platforms

Neoself Platform

AOI Bio. leverages a newly discovered mechanism, called Neoself, underlying autoimmune diseases to provide diagnostic services and support drug development efforts.

We currently offer testing services for the Anti-B2GPI Neoself Antibody in patients with
unexplained recurrent pregnancy or implantation failures.

Bioinformatics Analysis Platform

AOI Bio. employs advanced computational processing to help search for novel biomarkers and drug candidates.

We utilize the quantum-inspired optimization solution SQBM+, provided by our advanced computing partner Toshiba Digital Solutions, to identify allosteric pockets for drug development.

Company Information

Company name AOI Biosciences Inc.
Address 【Headquarters】
Niu Building 2F, 2-1-17, Nihombashi, Chuo-ku, Tokyo, 103-0027
【Neoself Testing Lab】
Research Institute for Microbial Diseases of Osaka University 3-1. Yamada, Suita, Osaka, 565-0871
Establish 2019年11月
Board Members and Advisors
  • Director, CEO Shinichi Sueta, MD
  • Director, COO Keiichi Kimura, Ph.D.
  • Director, CFO Shunsuke Ishii, CPA
  • Outside Director, Akihiro Ome
  • Auditor Hikaru Osawa(Attorney)
  • Scientific Advisor Yasushi Hirota(Professor, The University of Tokyo)